GVHD incidence in the 2 randomization arms
| . | Randomization arm . | P . | |
|---|---|---|---|
| CsA . | CsA/MTX . | ||
| Acute GVHD (69 evaluable patients) | |||
| No. of patients | 32 | 37 | |
| Absent | 13 (41%) | 17 (46%) | |
| Grade 1 | 7 (22%) | 9 (24%) | |
| Grade 2 | 12 (37%) | 10 (27%) | NS |
| Grade 3 | 0 (0%) | 1 (3%) | |
| Grade 4 | 0 (0%) | 0 (%) | |
| Organ involvement in acute GVHD (39 patients) | |||
| No. of patients | 19 | 20 | |
| Skin | 8 (42%) | 9 (45%) | NS |
| Liver | 1 (5%) | 0 (0%) | NS |
| Skin + intestine | 6 (32%) | 8 (40%) | NS |
| Skin + liver | 4 (21%) | 2 (10%) | NS |
| Skin + intestine + liver | 0 (0%) | 1 (5%) | NS |
| Chronic GVHD (66 evaluable patients) | |||
| No. of patients | 31 | 35 | |
| Absent | 22 (71%) | 21 (60%) | |
| Limited | 6 (19%) | 11 (31%) | NS |
| Extensive | 3 (10%) | 3 (9%) | |
| . | Randomization arm . | P . | |
|---|---|---|---|
| CsA . | CsA/MTX . | ||
| Acute GVHD (69 evaluable patients) | |||
| No. of patients | 32 | 37 | |
| Absent | 13 (41%) | 17 (46%) | |
| Grade 1 | 7 (22%) | 9 (24%) | |
| Grade 2 | 12 (37%) | 10 (27%) | NS |
| Grade 3 | 0 (0%) | 1 (3%) | |
| Grade 4 | 0 (0%) | 0 (%) | |
| Organ involvement in acute GVHD (39 patients) | |||
| No. of patients | 19 | 20 | |
| Skin | 8 (42%) | 9 (45%) | NS |
| Liver | 1 (5%) | 0 (0%) | NS |
| Skin + intestine | 6 (32%) | 8 (40%) | NS |
| Skin + liver | 4 (21%) | 2 (10%) | NS |
| Skin + intestine + liver | 0 (0%) | 1 (5%) | NS |
| Chronic GVHD (66 evaluable patients) | |||
| No. of patients | 31 | 35 | |
| Absent | 22 (71%) | 21 (60%) | |
| Limited | 6 (19%) | 11 (31%) | NS |
| Extensive | 3 (10%) | 3 (9%) | |